赖氨酸磷酸氢钙颗粒联合重组人生长激素对矮小症患儿生长发育的影响

陈立娟; 李斌; 杨丽昕; 敬小青

doi:10.13407/j.cnki.jpp.1672-108X.2022.01.012

您当前的位置：

首页 >

文章列表页 >

赖氨酸磷酸氢钙颗粒联合重组人生长激素对矮小症患儿生长发育的影响

论著 | 更新时间：2022-11-03

- 赖氨酸磷酸氢钙颗粒联合重组人生长激素对矮小症患儿生长发育的影响
- Effects of Lysine Hydrochloride and Calcium Hydrogen Phosphate Granules Combined with Recombinant Human Growth Hormone on Growth and Development of Children with Short Stature
- 儿科药学杂志 2022年28卷第1期页码：41-45
- 作者机构：
  
  承德医学院附属医院,河北,承德,067000
- 作者简介：
- 基金信息：
  
  承德市科学技术研究与发展计划项目,编号201801A22。
- DOI：10.13407/j.cnki.jpp.1672-108X.2022.01.012
  中图分类号：
- 纸质出版日期：2022，
扫描看全文
陈立娟, 李斌, 杨丽昕, 等. 赖氨酸磷酸氢钙颗粒联合重组人生长激素对矮小症患儿生长发育的影响[J]. 儿科药学杂志, 2022,28(1):41-45.

Chen Lijuan, Li Bin, Yang Lixin, et al. Effects of Lysine Hydrochloride and Calcium Hydrogen Phosphate Granules Combined with Recombinant Human Growth Hormone on Growth and Development of Children with Short Stature[J]. 2022,28(1):41-45.
陈立娟, 李斌, 杨丽昕, 等. 赖氨酸磷酸氢钙颗粒联合重组人生长激素对矮小症患儿生长发育的影响[J]. 儿科药学杂志, 2022,28(1):41-45. DOI： 10.13407/j.cnki.jpp.1672-108X.2022.01.012.

Chen Lijuan, Li Bin, Yang Lixin, et al. Effects of Lysine Hydrochloride and Calcium Hydrogen Phosphate Granules Combined with Recombinant Human Growth Hormone on Growth and Development of Children with Short Stature[J]. 2022,28(1):41-45. DOI： 10.13407/j.cnki.jpp.1672-108X.2022.01.012.

摘要

目的：分析赖氨酸磷酸氢钙颗粒联合重组人生长激素对矮小症患儿生长发育的影响。方法：选取2016年1月至2019年1月就诊于承德医学院附属医院的矮小症患儿60例，按完全随机法分为单药A组、单药B组和联合治疗组各20例，另外选取因各种原因未进行临床药物治疗的20例患儿为对照组。单药A组采用重组人生长激素治疗，单药B组采用赖氨酸磷酸氢钙颗粒治疗，联合治疗组采用赖氨酸磷酸氢钙颗粒联合重组人生长激素治疗。比较四组患儿生长发育情况及骨代谢指标骨钙素、骨碱性磷酸酶（bone alkaline phosphatase，BAP）、Ⅰ型胶原交联羧基末端肽（type Ⅰ collagen crosslinked carboxy-terminal peptide，ⅠCTP）、促甲状腺激素（thyrotropin，TSH）、胰岛素样生长因子1（insulin-like growth factor 1，IGF-1）、胰岛素样生长因子结合蛋白3（insulin-like growth factor binding protein 3，IGF-BP3）、维生素D、血钙、血磷、碱性磷酸酶水平，分析单药A组、单药B组、联合治疗组临床疗效及不良反应发生情况。结果：单药A组、单药B组、联合治疗组垂体MRI相关参数、生长速率、BMI、骨钙素、BAP、ⅠCTP、IGF-1、IGF-BP3、维生素D、血钙、血磷、碱性磷酸酶水平高于对照组（P<0.05）。联合治疗组身高、体质量、生长速率、BMI、骨钙素、BAP、ⅠCTP、IGF-1、IGF-BP3、维生素D、血钙、血磷、碱性磷酸酶水平高于单药A组、单药B组（P<0.05）。三组患儿临床疗效比较差异无统计学意义（P>0.05）。结论：赖氨酸磷酸氢钙颗粒联合重组人生长激素用于小儿矮小症疗效理想，可能通过改变垂体发育不良，补充机体维生素D，改善骨代谢异常，发挥其促进生长发育的作用。

Abstract

Objective: To analyze the effects of lysine hydrochloride and calcium hydrogen phosphate granules combined with recombinant human growth hormone on growth and development of children with short stature. Methods: A total of 60 children with short stature admitted into the Affiliated Hospital of Chengde Medical College from Jan. 2016 to Jan. 2019 were randomly divided into the single drug group A

single drug group B and combined treatment group

with 20 cases in each group. And 20 children that did not receive clinical drugs due to various reasons were selected as the control group. The single drug group A was treated with recombinant human growth hormone

the single drug group B was given lysine hydrochloride and calcium hydrogen phosphate granules

and the combined treatment group received lysine hydrochloride and calcium hydrogen phosphate granules combined with recombinant human growth hormone. Growth and bone metabolism indicators

osteocalcin

bone alkaline phosphatase (BAP)

type Ⅰ collagen crosslinked carboxy-terminal peptide (ⅠCTP)

thyrotropin (TSH)

insulin-like growth factor 1 (IGF-1)

insulin-like growth factor binding protein 3 (IGF-BP3)

vitamin D

blood calcium

blood phosphorus and alkaline phosphatase levels of four groups were compared. The clinical efficacy and adverse drug reactions of single drug group A

single drug group B and combined treatment group were analyzed. Results: Pituitary magnetic resonance imaging (MRI)-related parameters

growth rate

body mass index (BMI)

osteocalcin

calcitin

BAP

ⅠCTP

IGF-1

IGF-BP3

vitamin D

blood calcium

blood phosphorus

and alkaline phosphatase levels in the single drug group A

single drug group B and combined treatment group were higher than those in the control group (P<0.05). Height

body weight

growth rate

BMI

osteocalcin

BAP

ⅠCTP

IGF-1

IGF-BP3

vitamin D

blood calcium

blood phosphorus and alkaline phosphatase levels in the combined treatment group were higher than those in the single drug group A and single drug group B (P<0.05). There was no significant difference in clinical efficacy among three groups (P>0.05). Conclusion: The efficacy of lysine hydrochloride and calcium hydrogen phosphate granules combined with recombinant human growth hormone in the treatment of children with short stature is significant

which may play its role in promoting growth and development through changing the pituitary hypoplasia

supplementing the vitamin D and improving the abnormal bone metabolism.

关键词

赖氨酸磷酸氢钙颗粒重组人生长激素矮小症骨代谢生长发育

Keywords

lysine hydrochloride and calcium hydrogen phosphate granulesrecombinant human growth hormoneshort staturebone metabolismgrowth and development

references

查看原文

浏览量

下载量

CSCD

文章被引用时，请邮件提醒。

提交

工具集

关联资源

溴吡斯的明与左旋多巴联合激发试验峰值时间的探讨

重组人生长激素治疗儿童生长激素缺乏症的临床观察